mAb Das-1 recognizes 3'-Sulfated Lewis A/C, which is aberrantly expressed during metaplastic and oncogenic transformation of several gastrointestinal Epithelia

Introduction Multiple previous studies have shown the monoclonal antibody Das-1 (formerly called 7E(12)H(12)) is specifically reactive towards metaplastic and carcinomatous lesions in multiple organs of the gastrointestinal system (e.g. Barrett's esophagus, intestinal-type metaplasia of the stomach, gastric adenocarcinoma, high-grade pancreatic intraepithelial neoplasm, and pancreatic ductal adenocarcinoma) as well as in other organs (bladder and lung carcinomas). Beyond being a useful biomarker in tissue, mAb Das-1 has recently proven to be more accurate than current paradigms for identifying cysts harboring advanced neoplasia. Though this antibody has been used extensively for clinical, basic science, and translational applications for decades, its epitope has remained elusive. Methods In this study, we chemically deglycosylated a standard source of antigen, which resulted in near complete loss of the signal as measured by western blot analysis. The epitope recognized by mAb Das-1 was determined by affinity to a comprehensive glycan array and validated by inhibition of a direct ELISA. Results The epitope recognized by mAb Das-1 is 3'-Sulfo-Lewis A/C (3'-Sulfo-Le(A/C)). 3'-Sulfo-Le(A/C) is broadly reexpressed across numerous GI epithelia and elsewhere during metaplastic and carcinomatous transformation. Discussion 3'-Sulfo-Le(A/C) is a clinically important antigen that can be detected both intracellularly in tissue using immunohistochemistry and extracellularly in cyst fluid and serum by ELISA. The results open new avenues for tumorigenic risk stratification of various gastrointestinal lesions.

Automated summary

The epitope recognized by mAb Das-1 was identified as 3'-Sulfo-Lewis A/C, which is broadly reexpressed in gastrointestinal epithelia and other organs during metaplastic and carcinomatous transformation, and can be detected using immunohistochemistry and ELISA. These findings provide new avenues for tumor risk stratification in various gastrointestinal lesions.